Doris Hendig

List of Publications by Year
in descending order

66 papers	1,440 citations	257450 24 h-index	377865 34 g-index
66 all docs	66 docs citations	66 times ranked	1317 citing authors

#	Article	IF	Citations
1	Role of Serum Fetuin-A, a Major Inhibitor of Systemic Calcification, in Pseudoxanthoma Elasticum. Clinical Chemistry, 2006, 52, 227-234.	3.2	80
2	Centrifugal Fundus Abnormalities in Pseudoxanthoma Elasticum. Ophthalmology, 2010, 117, 1406-1414.	5.2	64
3	Pseudoxanthoma Elasticum: Genetic Variations in Antioxidant Genes Are Risk Factors for Early Disease Onset. Clinical Chemistry, 2007, 53, 1734-1740.	3.2	57
4	SPP1 Promoter Polymorphisms: Identification of the First Modifier Gene for Pseudoxanthoma Elasticum. Clinical Chemistry, 2007, 53, 829-836.	3.2	56
5	Reticular Pseudodrusen Associated With a Diseased Bruch Membrane in Pseudoxanthoma Elasticum. JAMA Ophthalmology, 2015, 133, 581.	2.5	56
6	Mutational analysis of theABCC6 gene and the proximalABCC6 gene promoter in German patients with pseudoxanthoma elasticum (PXE). Human Mutation, 2006, 27, 831-831.	2.5	55
7	Frequency, Phenotypic Characteristics and Progression of Atrophy Associated With a Diseased Bruch's Membrane in Pseudoxanthoma Elasticum. , 2016, 57, 3323.		55
8	Monthly Ranibizumab for Choroidal Neovascularizations Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: A One-Year Prospective Study. American Journal of Ophthalmology, 2011, 152, 695-703.	3.3	46
9	Elevated xylosyltransferase I activities in pseudoxanthoma elasticum (PXE) patients as a marker of stimulated proteoglycan biosynthesis. Journal of Molecular Medicine, 2005, 83, 984-992.	3.9	37
10	Gene expression profiling of ABC transporters in dermal fibroblasts of pseudoxanthoma elasticum patients identifies new candidates involved in PXE pathogenesis. Laboratory Investigation, 2008, 88, 1303-1315.	3.7	37
11	Choroidal Changes Associated With Bruch Membrane Pathology in Pseudoxanthoma Elasticum. American Journal of Ophthalmology, 2014, 158, 198-207.e3.	3.3	37
12	Ageing affects chondroitin sulfates and their synthetic enzymes in the intervertebral disc. Signal Transduction and Targeted Therapy, 2017, 2, 17049.	17.1	37
13	Vascular endothelial growth factor gene polymorphisms as prognostic markers for ocular manifestations in pseudoxanthoma elasticum. Human Molecular Genetics, 2009, 18, 3344-3351.	2.9	36
14	Human xylosyltransferase-I â€“ A new marker for myofibroblast differentiation in skin fibrosis. Biochemical and Biophysical Research Communications, 2013, 436, 449-454.	2.1	36
15	UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. PLoS ONE, 2015, 10, e0145478.	2.5	35
16	The local calcification inhibitor matrix Gla protein in pseudoxanthoma elasticum. Clinical Biochemistry, 2008, 41, 407-412.	1.9	34
17	Human xylosyltransferases â€“ mediators of arthrofibrosis? New pathomechanistic insights into arthrofibrotic remodeling after knee replacement therapy. Scientific Reports, 2015, 5, 12537.	3.3	34
18	Pyrophosphates as a major inhibitor of matrix calcification in Pseudoxanthoma elasticum. Journal of Dermatological Science, 2014, 75, 109-120.	1.9	33

#	Article	IF	Citations
19	New ABCC6 gene mutations in German pseudoxanthoma elasticum patients. Journal of Molecular Medicine, 2005, 83, 140-147.	3.9	30
20	ABCC6- a new player in cellular cholesterol and lipoprotein metabolism?. Lipids in Health and Disease, 2014, 13, 118.	3.0	29
21	Acute Retinopathy in Pseudoxanthoma Elasticum. JAMA Ophthalmology, 2019, 137, 1165.	2.5	29
22	Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays. Clinica Chimica Acta, 2018, 486, 347-356.	1.1	27
23	Characterization of the ATP-binding cassette transporter gene expression profile in Y79: a retinoblastoma cell line. Molecular and Cellular Biochemistry, 2009, 328, 85-92.	3.1	26
24	Large-Scaled Metabolic Profiling of Human Dermal Fibroblasts Derived from Pseudoxanthoma Elasticum Patients and Healthy Controls. PLoS ONE, 2014, 9, e108336.	2.5	26
25	Assessment of a rapid-cycle PCR assay for the identification of the recurrent c.3421C>T mutation in the ABCC6 gene in pseudoxanthoma elasticum patients. Laboratory Investigation, 2004, 84, 122-130.	3.7	25
26	Quantitative Fundus Autofluorescence in Pseudoxanthoma Elasticum. , 2017, 58, 6159.		24
27	IMPAIRED DARK ADAPTATION ASSOCIATED WITH A DISEASED BRUCH MEMBRANE IN PSEUDOXANTHOMA ELASTICUM. Retina, 2020, 40, 1988-1995.	1.7	24
28	Novel Mutations in the ABC6 Gene of German Patients with Pseudoxanthoma Elasticum. Human Biology, 2005, 77, 367-384.	0.2	23
29	Elevated circulating levels of matrix metalloproteinases MMP-2 and MMP-9 in pseudoxanthoma elasticum patients. Journal of Molecular Medicine, 2009, 87, 965-970.	3.9	23
30	Transglutaminase 2 regulates early chondrogenesis and glycosaminoglycan synthesis. Mechanisms of Development, 2011, 128, 234-245.	1.7	23
31	Analysis of Sequence Variations in the ABCC6 Gene among Patients with Abdominal Aortic Aneurysm and Pseudoxanthoma Elasticum. Journal of Vascular Research, 2005, 42, 424-432.	1.4	21
32	New insights into the pathogenesis of pseudoxanthoma elasticum and related soft tissue calcification disorders by identifying genetic interactions and modifiers. Frontiers in Genetics, 2013, 4, 114.	2.3	21
33	Identification of a xylosyltransferase II gene haplotype marker for diabetic nephropathy in type 1 diabetes. Clinica Chimica Acta, 2008, 398, 90-94.	1.1	14
34	Analysis of MMP2 promoter polymorphisms in patients with pseudoxanthoma elasticum. Clinica Chimica Acta, 2010, 411, 1487-1490.	1.1	14
35	Fast and sample cleanup-free measurement of nicotine and cotinine by stable isotope dilution ultra-performance liquid chromatographyâ€“tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2012, 67-68, 137-143.	2.8	14
36	Xylosyltransferase II is the predominant isoenzyme which is responsible for the steady-state level of xylosyltransferase activity in human serum. Biochemical and Biophysical Research Communications, 2015, 459, 469-474.	2.1	14

#	Article	IF	Citations
37	microRNA-29b mediates fibrotic induction of human xylosyltransferase-I in human dermal fibroblasts via the Sp1 pathway. Scientific Reports, 2018, 8, 17779.	3.3	14
38	Increased vascular occlusion in patients with pseudoxanthoma elasticum. Vasa - European Journal of Vascular Medicine, 2017, 46, 47-52.	1.4	14
39	Variants in genes encoding pyrophosphate metabolizing enzymes are associated with Pseudoxanthoma elasticum. Clinical Biochemistry, 2014, 47, 60-67.	1.9	12
40	Cellular and Molecular Biomarkers Indicate Premature Aging in Pseudoxanthoma Elasticum Patients. , 2020, 11, 536.		12
41	Characterization of dermal myofibroblast differentiation in pseudoxanthoma elasticum. Experimental Cell Research, 2017, 360, 153-162.	2.6	11
42	Retinal imaging including optical coherence tomography angiography for detecting active choroidal neovascularization in pseudoxanthoma elasticum. Clinical and Experimental Ophthalmology, 2019, 47, 240-249.	2.6	11
43	Linking ABCC6 Deficiency in Primary Human Dermal Fibroblasts of PXE Patients to p21-Mediated Premature Cellular Senescence and the Development of a Proinflammatory Secretory Phenotype. International Journal of Molecular Sciences, 2020, 21, 9665.	4.1	11
44	Genetic deletion of Abcc6 disturbs cholesterol homeostasis in mice. Scientific Reports, 2021, 11, 2137.	3.3	11
45	Assessment of a rapid-cycle PCR assay for the identification of the recurrent c.3421C>T mutation in the ABCC6 gene in pseudoxanthoma elasticum patients. Laboratory Investigation, 2004, 84, 122-130.	3.7	11
46	First description of the complete human xylosyltransferase-I promoter region. BMC Genetics, 2014, 15, 129.	2.7	10
47	microRNA-145 mediates xylosyltransferase-I induction in myofibroblasts via suppression of transcription factor KLF4. Biochemical and Biophysical Research Communications, 2020, 523, 1001-1006.	2.1	10
48	Abcc6 deficiency in mice leads to altered ABC transporter gene expression in metabolic active tissues. Lipids in Health and Disease, 2019, 18, 2.	3.0	9
49	Identification of Putative Non-Substrate-Based XT-I Inhibitors by Natural Product Library Screening. Biomolecules, 2020, 10, 1467.	4.0	8
50	Evidence of Long-Lasting Humoral and Cellular Immunity against SARS-CoV-2 Even in Elderly COVID-19 Convalescents Showing a Mild to Moderate Disease Progression. Life, 2021, 11, 805.	2.4	7
51	Copy number variation in the <scp>ATP</scp>â€binding cassette transporter <scp>ABCC6</scp> gene and <scp>ABCC6</scp> pseudogenes in patients with pseudoxanthoma elasticum. Molecular Genetics & Genomic Medicine, 2015, 3, 233-237.	1.2	6
52	Activin A-Mediated Regulation of XT-I in Human Skin Fibroblasts. Biomolecules, 2020, 10, 609.	4.0	6
53	Cytokine-mediated induction of human xylosyltransferase-I in systemic sclerosis skin fibroblasts. Biochemical and Biophysical Research Communications, 2021, 549, 34-39.	2.1	6
54	Elevated serum levels of intercellular adhesion molecule ICAM-1 in Pseudoxanthoma elasticum. Clinica Chimica Acta, 2008, 394, 54-58.	1.1	5

#	Article	IF	Citations
55	Carotid strain measurement in patients with pseudoxanthoma elasticum â€“ Hint for a different pathomechanism?. Intractable and Rare Diseases Research, 2018, 7, 25-31.	0.9	5
56	Retinal findings in carriers of monoallelic ABCC6 mutations. British Journal of Ophthalmology, 2020, 104, 1089-1092.	3.9	5
57	Development of a xylosyltransferase-I-selective UPLC MS/MS activity assay using a specific acceptor peptide. Biochimie, 2021, 184, 88-94.	2.6	5
58	First description of a compensatory xylosyltransferase I induction observed after an antifibrotic UDP-treatment of normal human dermal fibroblasts. Biochemical and Biophysical Research Communications, 2019, 512, 7-13.	2.1	4
59	Xylosyltransferase-deficient human HEK293â€¯cells show a strongly reduced proliferation capacity and viability. Biochemical and Biophysical Research Communications, 2020, 521, 507-513.	2.1	4
60	Statins as a Therapeutic Approach for the Treatment of Pseudoxanthoma Elasticum Patients: Evaluation of the Spectrum Efficacy of Atorvastatin In Vitro. Cells, 2021, 10, 442.	4.1	3
61	The Impact of Inflammatory Stimuli on Xylosyltransferase-I Regulation in Primary Human Dermal Fibroblasts. Biomedicines, 2022, 10, 1451.	3.2	3
62	Complement Factor H Variant p.Y402H in Pseudoxanthoma Elasticum Patients. Genetic Testing and Molecular Biomarkers, 2008, 12, 431-436.	1.7	2
63	Measurement of HMG CoA reductase activity in different human cell lines by ultra-performance liquid chromatography tandem mass spectrometry. Biochemical and Biophysical Research Communications, 2014, 443, 641-645.	2.1	2
64	Pulmonary affection of patients with Pseudoxanthoma elasticum: Long-term development and genotype-phenotype-correlation. Intractable and Rare Diseases Research, 2022, 11, 7-14.	0.9	1
65	Weiterbildung in der Klinischen Chemie und Laboratoriumsmedizin in Europa. Laboratoriums Medizin, 2013, 37, 275-285.	0.6	0
66	Identification and characterization of human xylosyltransferase II promoter single nucleotide variants. Biochemical and Biophysical Research Communications, 2015, 458, 901-907.	2.1	0